| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11029191 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews | 2019 | 5 Pages |
Abstract
PCSK9 inhibitors are used to reduce blood cholesterol levels as drugs. If it will be proven that PCSK9 can induce CD36 degradation, taking these drugs may have unwanted side effects. This study showed that serum PCSK9 and lipid profile levels increase in patients with subclinical hypothyroidism and there is no relationship between PCSK9 and CD36 in these patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
M. Fazaeli, A. Khoshdel, M. Shafiepour, M. Rohban,